Wednesday, April 17, 2013
Xencor Licenses Technology To Australian Firm
Monrovia, California-based biotherapeutics technology developer Xencor said Tuesday that it has licensed its Xtend technology to an Australian firm. Xencor and CSL Limited said they are in a technology license agreement, which will provide CSL access ot its technology, for use with CSL's monoclonal antibodies. Financial details of the license were not disclosed, however, the companies said that Xencor will receive an upfront payment plus preclinical, clinical, regulatory and sales milestone payments, as well as royalties on product sales.